Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Completes $75M Acquisition of MilliporeSigma's Flow Cytometry Portfolio

NEW YORK (GenomeWeb) – Luminex said today that it has completed its previously announced acquisition of MilliporeSigma's flow cytometry portfolio for $75 million in combined purchases of stock, assets, and inventory.

The newly acquired flow cytometry portfolio includes Amnis imaging flow cytometry products for cell-based analysis and the Guava portfolio of products, which leverage microcapillary technology and are also used for cell-based analysis.

Homi Shamir, president and CEO of Luminex, said in a statement that the acquired Amnis and Guava products complement Luminex's range of flow-based products. "This acquisition enables us to enhance our existing offering of flow-based detection systems, while simultaneously expanding our direct interactions with researchers conducting cellular analysis," he said.

With the acquisition, Luminex has expanded its installed base of flow cytometry systems to more than 5,000.

The firm said it anticipates that the acquisition will contribute $40 million to $50 million to its revenue in 2019. It said previously that the total acquisition fee consists of about $69.9 million to be paid under a stock and asset purchase agreement and about $5.1 million in committed inventory purchases.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.